United Therapeutics Corporation — Company profile
Healthcare · Drug Manufacturers - Specialty & Generic · United States
Last price 598.72 USD (Oct 30, 2026, 4:00 PM EST) · Market cap 25.68B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.
Details
| Name | United Therapeutics Corporation |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Employees | 1400 |
| Founded | 1996 |
| Ipo Date | 1999-06-17 |
| Ceo | Martine Rothblatt |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US91307C1027 |
| Cusip | 91307C102 |
| Cik | 0001082554 |
| Sic | 2834 |
Key executives
| Name | Title |
|---|---|
| Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D. | Founder, Chairman and Chief Executive Officer |
| Michael I. Benkowitz | President and Chief Operating Officer |
| James C. Edgemond | Chief Financial Officer and Treasurer |
| Paul A. Mahon J.D. | Executive Vice President, General Counsel and Corporate Secretary |
| Harrison Silvers | Manager of Investor Relations |
| Holly Hobson | Associate Vice President of Human Resources |
| Patrick Poisson | Executive Vice President of Strategic Development |
| Dr. Leigh Peterson | Executive Vice President of Product Development and Xenotransplantation |
| Gil Golden | Senior Vice President and Chief Medical Officer |
Contact
| Address | 1000 Spring Street, Silver Spring, Maryland 20910, United States |
| Phone | 301 608 9292 |
| Website | https://www.unither.com |